PD-L1 Biomarker Testing Market to Grow with a CAGR of 7.64% through 2028
Rising
demand
for predictive biomarker testing to guide therapy decisions are expected to
drive the Global PD-L1 Biomarker Testing Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “PD-L1
Biomarker Testing Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global PD-L1
Biomarker Testing Market stood at USD 1.54 billion in 2022 and is anticipated
to grow with a CAGR of 7.64% in the forecast period, 2024-2028. The Global
PD-L1 Biomarker Testing Market has witnessed remarkable growth in recent years,
driven by various factors that have transformed the landscape of cancer
diagnosis and treatment. Programmed Death-Ligand 1 (PD-L1) biomarker testing
has emerged as a crucial tool in the field of oncology, aiding clinicians in
making informed decisions regarding immunotherapy treatment strategies. One of the primary drivers behind the growth of the
PD-L1 biomarker testing market is the escalating global incidence of cancer.
Cancer remains a major public health concern, and the demand for effective and
targeted treatments is on the rise. PD-L1 testing helps identify patients who
are likely to benefit from immune checkpoint inhibitor therapies, such as PD-1
and PD-L1 inhibitors, thereby enhancing the precision and efficacy of cancer
treatment. Immunotherapy has revolutionized cancer treatment by harnessing the
body's immune system to target and destroy cancer cells. PD-L1 biomarker
testing is crucial in identifying patients who are suitable candidates for
immunotherapy. The remarkable success of immune checkpoint inhibitors in
various cancer types, including non-small cell lung cancer (NSCLC), melanoma,
and bladder cancer, has led to increased demand for PD-L1 testing, as
clinicians seek to optimize patient outcomes.
The era of personalized medicine is gaining momentum,
with healthcare providers increasingly focusing on tailoring treatments to
individual patients. PD-L1 biomarker testing is a prime example of this
approach, as it helps identify patients who are most likely to respond
positively to immunotherapy, sparing others from potentially ineffective and
harsh treatments. This personalized approach not only improves patient outcomes
but also reduces healthcare costs. Initially, PD-L1 testing was primarily
associated with NSCLC. However, its applications have expanded to include
various cancer types, such as breast cancer, gastric cancer, head and neck
cancer, and more. This broader range of applications has contributed
significantly to the market's growth, as it addresses the needs of a larger
patient population.
Advances in diagnostic technologies have played a
pivotal role in the growth of the PD-L1 biomarker testing market. Various
testing methods, including immunohistochemistry (IHC), polymerase chain
reaction (PCR), and next-generation sequencing (NGS), have become more precise,
reliable, and accessible. These technological advancements have not only
improved the accuracy of PD-L1 testing but have also made it more
cost-effective.
The Global PD-L1 Biomarker Testing Market is segmented
into Cancer Type, Assay Kit Type, End Use, Regional Distribution, And Company.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "PD-L1 Biomarker Testing Market.”
Based on the Cancer Type, the Non-Small Cell Lung
Cancer (NSCLC) emerged as the dominant segment in the global market for Global
PD-L1 Biomarker Testing Market in 2022. NSCLC is one of the most common types
of lung cancer, and lung cancer itself is one of the most prevalent cancers
worldwide. It accounts for a significant portion of all cancer diagnoses
globally, making it a major public health concern. The success of immune
checkpoint inhibitors, including PD-1 and PD-L1 inhibitors, has revolutionized the
treatment of NSCLC. These immunotherapies have shown remarkable efficacy in a
subset of NSCLC patients, leading to an increased demand for PD-L1 testing to
identify those who are most likely to benefit.
Based on
the Assay Kit Type, the PD-L1 22C3 IHC segment emerged as the dominant player
in the global market for Global PD-L1 Biomarker Testing Market in 2022.
The PD-L1
22C3 IHC assay kit is associated with pembrolizumab (Keytruda), a widely used
immune checkpoint inhibitor. It has received companion diagnostic status from
regulatory agencies like the U.S. Food and Drug Administration (FDA) for
several cancer types, including non-small cell lung cancer (NSCLC) and head and
neck squamous cell carcinoma. This official recognition of the PD-L1 22C3 IHC
assay kit as a companion diagnostic test has significantly boosted its demand. The
PD-L1 22C3 IHC assay kit has undergone extensive clinical validation, providing
robust and reliable results.
Based on the End Use, the Diagnostics
segment emerged as the dominant player in the global market for Global PD-L1
Biomarker Testing Market in 2022. PD-L1 biomarker testing is primarily used for
clinical purposes in the diagnosis and treatment of cancer. The clinical
diagnostics segment includes testing conducted in healthcare settings to guide
treatment decisions for cancer patients. As the market's primary driver, the
demand for PD-L1 testing in clinical diagnostics is substantial. The primary
objective of PD-L1 biomarker testing is to improve patient care by providing
oncologists with critical information about a patient's likelihood of
responding to immunotherapy. Clinicians rely on these test results to make
informed treatment decisions, ensuring that patients receive the most
appropriate and effective therapies.
North America emerged as the dominant player in the
global PD-L1 Biomarker Testing Market in 2022, holding the largest market
share. North America boasts one of the most advanced healthcare infrastructures
globally. The region is equipped with state-of-the-art clinical laboratories,
medical facilities, and skilled healthcare professionals, making it
well-prepared for the adoption of cutting-edge diagnostic technologies like
PD-L1 biomarker testing. North America has a relatively high incidence of
cancer, with lung cancer being one of the most prevalent types. PD-L1 biomarker
testing is particularly critical in guiding treatment decisions for lung cancer
patients, which contributes to the substantial demand for PD-L1 testing in the
region.
Major companies operating in Global PD-L1
Biomarker Testing Market are:
- AstraZeneca PLC
- Merck Group (SigmaAldrich Co., LLC)
- F. Hoffmann-La Roche Ltd.
- Abcam
- Agilent technologies
- NeoGenomics Laboratories, Inc.
- ACROBiosystems
- PerkinElmer Inc.
- Guardant Health
- Quanterix
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The Global
PD-L1 Biomarker Testing Market is poised for substantial growth in the coming
years. Anticipated drivers include the continuous rise in cancer incidence,
particularly in developing regions, necessitating more precise diagnostic tools
for treatment decisions. The success of immunotherapy, with immune checkpoint
inhibitors at the forefront, is driving the demand for PD-L1 biomarker testing
to identify suitable candidates for these therapies, as well as to monitor
treatment response. Technological advancements in testing methods and increased
standardization efforts are expected to improve the accuracy and accessibility
of PD-L1 testing, further fueling market expansion. Additionally, the expansion
of PD-L1 testing applications across various cancer types, beyond its initial
association with non-small cell lung cancer, broadens its relevance and market
potential.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“PD-L1 Biomarker Testing Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Cancer
Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others),
By Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142),
By End Use (Research and Development, Diagnostics) By Region and Competition”, has evaluated
the future growth potential of Global PD-L1 Biomarker Testing Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global PD-L1 Biomarker Testing Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com